BackBioventus Overview

Bioventus Long Term Debt

Latest long-term debt for BVS: $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00
↓ 100.00% YoYΔ $-308.59M vs prior year quarter

Peer average

Loading

Bioventus Long Term Debt History

Loading

Bioventus vs. peers: Long Term Debt Comparison

Loading

Bioventus Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Bioventus (BVS) FAQ

As of the most recent data (March 2026), BVS shows a long-term debt of $0. That compares with $310M in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BVS's long-term debt is now $0 (was $310M) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Bioventus is outperforming or lagging.

Tracking BVS's long-term debt over time shows whether Bioventus is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $310M in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Bioventus's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.

Bioventus's long-term debt is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.